신경 인지 바이오마커 솔루션 시장 예측(-2034년) : 바이오마커 유형, 기술, 적응증, 샘플 유형, 최종사용자 및 지역별 세계 분석

According to Stratistics MRC, the Global Neurocognitive Biomarker Solutions Market is accounted for $5.2 billion in 2026 and is expected to reach $19.8 billion by 2034 growing at a CAGR of 18.2% during the forecast period. Neurocognitive biomarker solutions are advanced technologies that identify, measure, and analyze biological and digital indicators associated with cognitive function, neurological disorders, and brain health. These solutions combine neuroimaging, blood-based biomarkers, electrophysiological measurements, wearable sensors, artificial intelligence, and digital cognitive assessments to support early diagnosis, disease monitoring, treatment selection, and personalized care. Neurocognitive biomarker solutions are widely used in clinical research, hospitals, pharmaceutical development, and precision medicine. Growing prevalence of neurological disorders and increasing investment in biomarker-based diagnostics are driving the global adoption of neurocognitive biomarker solutions.

Market Dynamics:

Driver:

Rising neurological disease prevalence

Global prevalence of neurological disorders such as autism spectrum conditions, ADHD, and developmental delays is steadily increasing. This trend is fueling demand for AI-driven screening tools that enable earlier detection and intervention. Enterprises are investing in advanced algorithms to improve diagnostic accuracy and reduce reliance on traditional methods. Governments are supporting neurodevelopment initiatives through healthcare funding and policy frameworks. Families and caregivers increasingly seek accessible, non-invasive screening methods for children and adults. Advances in machine learning and multimodal data integration enhance predictive capabilities. Collectively, these factors ensure strong momentum for AI-based neurodevelopment screening adoption.

Restraint:

Complex biomarker validation processes

Validation of biomarkers requires extensive clinical trials and regulatory approvals, which slows down commercialization. Enterprises face high costs and long timelines in developing clinically reliable biomarkers. Smaller firms struggle to manage validation compared to larger competitors with advanced research capacity. Regulatory frameworks demand rigorous evidence before approval, adding complexity. Consumer trust in AI-based screening depends on validated biomarkers that demonstrate accuracy. The need for standardized protocols across regions further complicates adoption. As a result, biomarker validation remains a significant barrier to rapid market growth.

Opportunity:

Blood-based biomarker innovations

Blood-based biomarkers offer a promising pathway for non-invasive neurodevelopment screening. Innovations in this area present opportunities to expand AI-based diagnostics beyond imaging. Enterprises benefit from improved accessibility and reduced reliance on costly neuroimaging techniques. Governments are encouraging biomarker research as part of precision medicine strategies. Families increasingly demand simple and reliable screening methods, accelerating investment in blood-based solutions. Advances in AI integration enhance the predictive power of biomarker analysis.

Threat:

Lengthy clinical approval timelines

Clinical approval processes for AI-based screening tools are lengthy and complex, delaying commercialization. Enterprises must invest heavily in compliance and regulatory submissions. Smaller firms are particularly vulnerable compared to larger competitors with established regulatory expertise. Governments emphasize patient safety, which adds further delays to approvals. Consumers face limited access to innovative tools until regulatory clearance is achieved. The slow pace of approvals reduces incentives for rapid innovation. Unless timelines are streamlined, lengthy approval processes will remain a challenge.

Covid-19 Impact:

The pandemic disrupted clinical trials and slowed down biomarker validation efforts. Lockdowns delayed research activities and reduced short-term adoption of new screening tools. At the same time, the crisis highlighted the importance of remote and AI-driven healthcare solutions. Governments emphasized digital health in recovery plans, reinforcing the role of AI-based screening. Enterprises renewed focus on scalable and adaptive technologies to ensure continuity of care. Families became more aware of neurological health needs during the crisis.

The imaging biomarkers segment is expected to be the largest during the forecast period

The imaging biomarkers segment is expected to account for the largest market share during the forecast period as these tools provide detailed insights into brain structure and function. Enterprises rely on imaging biomarkers to support early diagnosis and intervention. Governments are prioritizing imaging research as part of neurodevelopment initiatives. Families benefit from improved accuracy and reliability in screening outcomes. Advances in AI-driven image analysis enhance scalability and predictive power. Public-private partnerships are accelerating deployment in clinical settings.

The artificial intelligence segment is expected to have the highest CAGR during the forecast period

Over the forecast period, the artificial intelligence segment is predicted to witness the highest growth rate due to rising demand for predictive analytics and adaptive screening solutions. Enterprises are adopting AI-driven platforms to improve diagnostic accuracy and efficiency. Governments are supporting AI integration in healthcare frameworks. Families increasingly demand accessible and intelligent screening tools. Advances in machine learning and deep learning enhance predictive capabilities. Smaller firms find opportunities in niche AI applications within neurodevelopment.

Region with largest share:

During the forecast period, the North America region is expected to hold the largest market share owing to strong healthcare infrastructure and early adoption of AI technologies. The U.S. leads in deploying AI-based screening tools across hospitals and research institutions. Enterprises are investing heavily in advanced algorithms and biomarker research. Families demand reliable and accessible screening solutions at higher rates compared to other regions. Regulatory frameworks support innovation while ensuring compliance. Governments are funding pilot projects for neurodevelopment screening. These factors collectively secure North America's leadership.

Region with highest CAGR:

Over the forecast period, the Asia Pacific region is anticipated to exhibit the highest CAGR driven by rapid digitalization and expanding healthcare investments. Countries such as China, India, and Japan are scaling up AI-based healthcare projects to meet rising neurological health needs. Growing middle-class populations are fueling demand for accessible screening solutions. Governments are introducing supportive policies to encourage domestic innovation in AI healthcare. Local companies are expanding production to meet both domestic and export requirements. Advances in blood-based biomarkers and AI-driven analytics accelerate adoption in this region.

Key players in the market

Some of the key players in Neurocognitive Biomarker Solutions Market include Roche Holding AG, QUIBIM S.L., C2N Diagnostics LLC, Biogen Inc., Philips Healthcare, Siemens Healthineers AG, GE HealthCare Technologies Inc., FUJIFILM Holdings Corporation, Canon Medical Systems Corporation, Natus Medical Incorporated, Compumedics Limited, Neuroelectrics S.L., EMOTIV Inc., BrainScope Company, Inc. and Quest Diagnostics Incorporated.

Key Developments:

In June 2026, C2N Diagnostics LLC partnered with SouthGenetics to commercialize its PrecivityAD2 blood test across international markets. The high-resolution mass spectrometry assay detects plasma p-tau217 and amyloid ratios to accurately identify early Alzheimer's pathology.

In February 2026, Biogen Inc. integrated a portfolio of novel digital and fluid biomarker assays into its late-stage neurodegeneration trials. The multi-modal monitoring framework tracks target engagement and cognitive stabilization in patients receiving disease-modifying therapies.

Biomarker Types Covered:

• Imaging Biomarkers
• Electrophysiological Biomarkers
• Digital Biomarkers
• Molecular Biomarkers
• Other Biomarker Types

Technologies Covered:

• Artificial Intelligence
• Neuroimaging
• Electroencephalography (EEG)
• Blood-Based Analysis
• Other Technologies

Clinical Indications Covered:

• Neurodegenerative Disorders
• Neurodevelopmental Disorders
• Traumatic Brain Injury
• Psychiatric Disorders
• Other Clinical Indications

Sample Types Covered:

• Blood
• Cerebrospinal Fluid
• Brain Imaging Data
• Digital Physiological Data
• Other Sample Types

End Users Covered:

• Hospitals
• Diagnostic Laboratories
• Research Institutes
• Pharmaceutical Companies
• Other End Users

Regions Covered:

• North America
  • United States
  • Canada
  • Mexico
• Europe
  • United Kingdom
  • Germany
  • France
  • Italy
  • Spain
  • Netherlands
  • Belgium
  • Sweden
  • Switzerland
  • Poland
  • Rest of Europe
• Asia Pacific
  • China
  • Japan
  • India
  • South Korea
  • Australia
  • Indonesia
  • Thailand
  • Malaysia
  • Singapore
  • Vietnam
  • Rest of Asia Pacific
• South America
  • Brazil
  • Argentina
  • Colombia
  • Chile
  • Peru
  • Rest of South America
• Rest of the World (RoW)
  • Middle East
• Saudi Arabia
• United Arab Emirates
• Qatar
• Israel
• Rest of Middle East
  • Africa
• South Africa
• Egypt
• Morocco
• Rest of Africa

What our report offers:

• Market share assessments for the regional and country-level segments
• Strategic recommendations for the new entrants
• Covers Market data for the years 2023, 2024, 2025, 2026, 2027, 2028, 2030, 2032 and 2034
• Market Trends (Drivers, Constraints, Opportunities, Threats, Challenges, Investment Opportunities, and recommendations)
• Strategic recommendations in key business segments based on the market estimations
• Competitive landscaping mapping the key common trends
• Company profiling with detailed strategies, financials, and recent developments
• Supply chain trends mapping the latest technological advancements

Free Customization Offerings:

All the customers of this report will be entitled to receive one of the following free customization options:

• Company Profiling
  • Comprehensive profiling of additional market players (up to 3)
  • SWOT Analysis of key players (up to 3)
• Regional Segmentation
  • Market estimations, Forecasts and CAGR of any prominent country as per the client's interest (Note: Depends on feasibility check)
• Competitive Benchmarking
  • Benchmarking of key players based on product portfolio, geographical presence, and strategic alliances

Table of Contents

1 Executive Summary

• 1.1 Market Snapshot and Key Highlights
• 1.2 Growth Drivers, Challenges, and Opportunities
• 1.3 Competitive Landscape Overview
• 1.4 Strategic Insights and Recommendations

2 Research Framework

• 2.1 Study Objectives and Scope
• 2.2 Stakeholder Analysis
• 2.3 Research Assumptions and Limitations
• 2.4 Research Methodology
  • 2.4.1 Data Collection (Primary and Secondary)
  • 2.4.2 Data Modeling and Estimation Techniques
  • 2.4.3 Data Validation and Triangulation
  • 2.4.4 Analytical and Forecasting Approach

3 Market Dynamics and Trend Analysis

• 3.1 Market Definition and Structure
• 3.2 Key Market Drivers
• 3.3 Market Restraints and Challenges
• 3.4 Growth Opportunities and Investment Hotspots
• 3.5 Industry Threats and Risk Assessment
• 3.6 Technology and Innovation Landscape
• 3.7 Emerging and High-Growth Markets
• 3.8 Regulatory and Policy Environment
• 3.9 Impact of COVID-19 and Recovery Outlook

4 Competitive and Strategic Assessment

• 4.1 Porter's Five Forces Analysis
  • 4.1.1 Supplier Bargaining Power
  • 4.1.2 Buyer Bargaining Power
  • 4.1.3 Threat of Substitutes
  • 4.1.4 Threat of New Entrants
  • 4.1.5 Competitive Rivalry
• 4.2 Market Share Analysis of Key Players
• 4.3 Product Benchmarking and Performance Comparison

5 Global Neurocognitive Biomarker Solutions Market, By Biomarker Type

• 5.1 Imaging Biomarkers
• 5.2 Electrophysiological Biomarkers
• 5.3 Digital Biomarkers
• 5.4 Molecular Biomarkers
• 5.5 Other Biomarker Types

6 Global Neurocognitive Biomarker Solutions Market, By Technology

• 6.1 Artificial Intelligence
• 6.2 Neuroimaging
• 6.3 Electroencephalography (EEG)
• 6.4 Blood-Based Analysis
• 6.5 Other Technologies

7 Global Neurocognitive Biomarker Solutions Market, By Clinical Indication

• 7.1 Neurodegenerative Disorders
• 7.2 Neurodevelopmental Disorders
• 7.3 Traumatic Brain Injury
• 7.4 Psychiatric Disorders
• 7.5 Other Clinical Indications

8 Global Neurocognitive Biomarker Solutions Market, By Sample Type

• 8.1 Blood
• 8.2 Cerebrospinal Fluid
• 8.3 Brain Imaging Data
• 8.4 Digital Physiological Data
• 8.5 Other Sample Types

9 Global Neurocognitive Biomarker Solutions Market, By End User

• 9.1 Hospitals
• 9.2 Diagnostic Laboratories
• 9.3 Research Institutes
• 9.4 Pharmaceutical Companies
• 9.5 Other End Users

10 Global Neurocognitive Biomarker Solutions Market, By Geography

• 10.1 North America
  • 10.1.1 United States
  • 10.1.2 Canada
  • 10.1.3 Mexico
• 10.2 Europe
  • 10.2.1 United Kingdom
  • 10.2.2 Germany
  • 10.2.3 France
  • 10.2.4 Italy
  • 10.2.5 Spain
  • 10.2.6 Netherlands
  • 10.2.7 Belgium
  • 10.2.8 Sweden
  • 10.2.9 Switzerland
  • 10.2.10 Poland
  • 10.2.11 Rest of Europe
• 10.3 Asia Pacific
  • 10.3.1 China
  • 10.3.2 Japan
  • 10.3.3 India
  • 10.3.4 South Korea
  • 10.3.5 Australia
  • 10.3.6 Indonesia
  • 10.3.7 Thailand
  • 10.3.8 Malaysia
  • 10.3.9 Singapore
  • 10.3.10 Vietnam
  • 10.3.11 Rest of Asia Pacific
• 10.4 South America
  • 10.4.1 Brazil
  • 10.4.2 Argentina
  • 10.4.3 Colombia
  • 10.4.4 Chile
  • 10.4.5 Peru
  • 10.4.6 Rest of South America
• 10.5 Rest of the World (RoW)
  • 10.5.1 Middle East
    • 10.5.1.1 Saudi Arabia
    • 10.5.1.2 United Arab Emirates
    • 10.5.1.3 Qatar
    • 10.5.1.4 Israel
    • 10.5.1.5 Rest of Middle East
  • 10.5.2 Africa
    • 10.5.2.1 South Africa
    • 10.5.2.2 Egypt
    • 10.5.2.3 Morocco
    • 10.5.2.4 Rest of Africa

11 Strategic Market Intelligence

• 11.1 Industry Value Network and Supply Chain Assessment
• 11.2 White-Space and Opportunity Mapping
• 11.3 Product Evolution and Market Life Cycle Analysis
• 11.4 Channel, Distributor, and Go-to-Market Assessment

12 Industry Developments and Strategic Initiatives

• 12.1 Mergers and Acquisitions
• 12.2 Partnerships, Alliances, and Joint Ventures
• 12.3 New Product Launches and Certifications
• 12.4 Capacity Expansion and Investments
• 12.5 Other Strategic Initiatives

13 Company Profiles

• 13.1 Roche Holding AG
• 13.2 QUIBIM S.L.
• 13.3 C2N Diagnostics LLC
• 13.4 Biogen Inc.
• 13.5 Philips Healthcare
• 13.6 Siemens Healthineers AG
• 13.7 GE HealthCare Technologies Inc.
• 13.8 FUJIFILM Holdings Corporation
• 13.9 Canon Medical Systems Corporation
• 13.10 Natus Medical Incorporated
• 13.11 Compumedics Limited
• 13.12 Neuroelectrics S.L.
• 13.13 EMOTIV Inc.
• 13.14 BrainScope Company, Inc.
• 13.15 Quest Diagnostics Incorporated